J
Joy Ross
Researcher at St Christopher's Hospice
Publications - 48
Citations - 2049
Joy Ross is an academic researcher from St Christopher's Hospice. The author has contributed to research in topics: Palliative care & Opioid. The author has an hindex of 19, co-authored 43 publications receiving 1943 citations. Previous affiliations of Joy Ross include The Royal Marsden NHS Foundation Trust & Imperial College London.
Papers
More filters
Journal ArticleDOI
A systematic review of the role of bisphosphonates in metastatic disease.
TL;DR: Most evidence supports the use of intravenous aminobisphosphonates in breast cancer patients where fractures are prevented, and economic modelling showed that for acute hypercalcaemia, drugs with the longest cumulative duration of normocalcaemia were most cost-effective.
Journal ArticleDOI
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer
TL;DR: In people with metastatic bone disease bisphosphonates significantly decrease skeletal morbidity, except for spinal cord compression and increased time to first skeletal related event.
Journal ArticleDOI
Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain.
TL;DR: This study suggests that genetic variability in the COMT gene influence the efficacy of morphine in cancer patients with pain, and that increased understanding of this variability is reached by expanding from analyses of single SNPs to haplotype construction and analyses.
Journal ArticleDOI
Clinical response to morphine in cancer patients and genetic variation in candidate genes
Joy Ross,Joy Ross,D Rutter,D Rutter,Kenneth I. Welsh,S P Joel,K Goller,Athol U. Wells,R M du Bois,Julia Riley +9 more
TL;DR: No differences were seen in genotype or allele frequencies of SNPs in the μ-opioid receptor gene or UGT2B7 gene, in patients who responded to morphine vs those who were switched to alternative opioids.
Journal ArticleDOI
Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
Joy Ross,Julia Riley,Annie B. Taegetmeyer,Hiroe Sato,Sophy K. Gretton,Sophy K. Gretton,Roland M. du Bois,Kenneth I. Welsh +7 more
TL;DR: Pain is a common symptom for patients with cancer, and opioids are the treatment of choice for moderate or severe cancer‐related pain, but central side effects can limit the use of opioids in clinical practice.